This article was paid for by a contributing third party.More Information.
Tackling buy-side OTC derivatives challenges: Regulations, risks and collateral management
THE PANEL
- Glenn Barry, managing director, derivatives and quantitative strategies, Sun Life Investment Management
- Lisa Cavallari, director of fixed income derivatives and commodities, Russell Investments
- Sylvain Privat, head of product management, investment management solutions, Calypso Technology
- James Wallin, senior vice-president, AllianceBernstein
- Moderator: Duncan Wood, editor-in-chief, Risk.net
Despite a steady increase in the use of derivatives among investment managers, research from Asia Risk indicates many firms are still facing serious regulatory and technology challenges.
In a recent Asia Risk survey, an overwhelming 80% of the respondents said that over-the-counter derivatives were a concern from both a risk management and operations perspective. In addition, 60% say they do not have real-time, intra-day access to their collateral inventory, while 70% are not able to optimise their collateral on a pre-trade basis.
Sponsored content
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@risk.net
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@risk.net